Actinic Keratosis (Solar Keratosis)

What is Actinic Keratosis?

Actinic keratosis (AK), also called solar keratosis, is a **premalignant skin lesion** that appears on areas of skin that have been exposed to long‑term ultraviolet (UV) radiation. The lesions are typically small (a few millimeters to 1–2 cm), rough, and may feel like a sandpaper patch. Although most AKs remain benign, a small percentage can progress to squamous cell carcinoma (SCC), the second most common form of skin cancer.

AK is most common in adults over the age of 40, especially those with fair skin (Fitzpatrick skin types I‑III). The condition reflects cumulative DNA damage in the keratinocytes (the predominant cells of the epidermis) caused by chronic UV exposure.

Common Causes

While UV radiation is the principal driver, several other factors increase the risk of developing actinic keratosis:

• Chronic Sun Exposure – Outdoor work or recreation without adequate sun protection.
• History of Sunburns – Especially blistering burns during childhood or adolescence.
• Fair Skin, Red or Blonde Hair, Light Eyes – Less melanin provides less natural protection.
• Advanced Age – DNA repair mechanisms decline with age.
• Immune Suppression – Organ‑transplant recipients, HIV infection, or long‑term corticosteroid use.
• Geographic Location – Living at high altitude or near the equator where UV intensity is higher.
• Exposure to Certain Chemicals – Arsenic, polycyclic aromatic hydrocarbons, and some industrial solvents can act as photosensitizers.
• Tobacco Use – Smoking has been linked to an increased risk of AK and SCC.
• Previous Skin Cancer – A personal history of basal cell carcinoma (BCC) or SCC raises the likelihood of new AKs.
• Genetic Predisposition – Rare inherited disorders affecting DNA repair (e.g., xeroderma pigmentosum).

Associated Symptoms

Actinic keratoses are often asymptomatic, but patients may notice the following:

• Small, rough, scaly or crusty patches on sun‑exposed skin (face, ears, scalp, forearms, hands, lower legs).
• Red or flesh‑colored lesions that may be slightly raised.
• Itching, burning, or tenderness, especially after sun exposure.
• Bleeding or crusting if the lesion is traumatized.
• Occasional development of a “wart‑like” growth that can be mistaken for a benign wart.

Most AKs appear singly, but many patients develop **multiple** lesions—sometimes dozens—forming what dermatologists call “field cancerization.”

When to See a Doctor

Because AK can evolve into squamous cell carcinoma, any new, changing, or symptomatic skin lesion on a sun‑exposed area warrants evaluation. Seek medical attention promptly if you notice:

• Lesions that grow in size, become raised, or develop a firm nodule.
• Persistent bleeding, ulceration, or a sore that does not heal within 2–3 weeks.
• Newer lesions that look different from other AKs (e.g., more pigmented, nodular, or painful).
• Any lesion on the lips, ears, or around the eyes—areas where SCC can spread rapidly.
• Signs of infection: redness, warmth, pus, or fever.

Early evaluation by a dermatologist can prevent progression to invasive cancer.

Diagnosis

Diagnosis relies on a combination of visual inspection, dermoscopic evaluation, and occasionally biopsy.

Clinical Examination

• Visual inspection – A trained clinician looks for the characteristic rough, sandpaper‑like texture and color.
• Dermatoscopy – A handheld magnifier that reveals specific vascular patterns (e.g., “strawberry pattern”) that differentiate AK from benign lesions.

Skin Biopsy

If the lesion looks atypical or the diagnosis is uncertain, a punch or shave biopsy is performed. Pathology confirms:

• Presence of atypical keratinocytes confined to the epidermis (intraepidermal dysplasia).
• Evidence of early invasive SCC, if present.

Additional Tools

• Photographic documentation – Helps track changes over time, especially in patients with multiple lesions.
• Field cancerization mapping – Using tools like reflectance confocal microscopy (RCM) can reveal subclinical lesions.

Treatment Options

Therapy aims to eradicate visible lesions, treat the surrounding “field” of damaged skin, and reduce the risk of SCC. Treatment choice depends on lesion size, number, location, patient’s health, and cosmetic considerations.

Topical Pharmacologic Therapies

• 5‑Fluorouracil (5‑FU) cream 5% or 4%: Causes selective death of dysplastic keratinocytes. Treatment lasts 2–4 weeks; skin redness and crusting are expected.
• Imiquimod 5% cream: An immune response modifier that induces cytokine release. Applied 2–3 times per week for up to 12 weeks.
• Diclofenac gel 3% (with hyaluronic acid): Anti‑inflammatory approach, typically used for 2–3 months.
• Ingenol mebutate (Picato) 0.015% (face/scalp) or 0.05% (body): Short‑course (2–3 days) that triggers rapid cell death and immune‑mediated clearance.

Procedural Options

• Cryotherapy: Liquid nitrogen applied for 10–15 seconds; ideal for isolated lesions.
• Electrosurgery & curettage: Scraping the lesion followed by electric cautery; useful for thicker AKs.
• Laser therapy (e.g., ablative CO₂ or Er:YAG): Precise removal of superficial lesions and field treatment.
• Photodynamic therapy (PDT): Application of a photosensitizing agent (e.g., aminolevulinic acid) followed by red‑light illumination; excellent for treating multiple lesions across a field.
• Excision: Reserved for lesions suspicious for invasive SCC; provides a tissue sample for pathology.

Home & Supportive Care

• Gentle cleansing with mild, fragrance‑free soap.
• Moisturize with a non‑comedogenic, barrier‑repair cream to reduce irritation from topical agents.
• Sun avoidance during active treatment (e.g., 2 weeks after 5‑FU) to limit severe phototoxic reactions.

Follow‑up

Patients with a history of AK should be examined by a dermatologist at least annually, or more frequently if they have many lesions or risk factors such as immune suppression.

Prevention Tips

Because the root cause is UV exposure, the most effective strategy is diligent sun protection combined with skin surveillance.

• Daily Broad‑Spectrum Sunscreen: SPF 30 or higher, reapplied every 2 hours outdoors and after swimming or sweating.
• Protective Clothing: Wide‑brimmed hats, UPF‑rated shirts, long sleeves, and UV‑blocking sunglasses.
• Avoid Peak Sun Hours: Stay in shade between 10 am and 4 pm when UV intensity peaks.
• Regular Skin Checks: Perform a self‑exam monthly; look for new or changing lesions.
• Professional Skin Exams: Dermatologist visits at least once a year, more often if you have many AKs or a prior skin cancer.
• Quit Smoking: Reduces overall skin cancer risk.
• Limit Tanning Beds: Artificial UV radiation carries the same risk as sun exposure.
• Vitamin D Awareness: Obtain vitamin D from diet or supplements rather than intentional sun exposure.
• Protect Immunocompromised Patients: Extra vigilance for organ‑transplant recipients and those on long‑term immunosuppressants.

Emergency Warning Signs

Key Takeaways

Actinic keratosis is a common, UV‑related skin condition that serves as a warning sign for potential skin cancer. Early recognition, prompt treatment, and diligent sun‑protective behavior dramatically lower the risk of progression to squamous cell carcinoma. If you notice any suspicious skin changes, especially those that bleed, ulcerate, or evolve rapidly, schedule a dermatology appointment without delay.

Sources: Mayo Clinic, American Academy of Dermatology, National Cancer Institute, CDC Skin Cancer Prevention Guidelines, Cleveland Clinic, peer‑reviewed journals (JAMA Dermatology, British Journal of Dermatology). Information reviewed 2024‑2025.